PerkinElmer
check quantity

VivoTag 800 Fluorochrome (5mg)

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications.

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
NEV11108
683.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

VivoTag 800 fluorochrome is an amine-reactive near-infrared fluorochrome for coupling via a NHS ester linkage to peptides, small molecules, proteins, antibodies or macromolecules. Available is 5 mg quantity.

Specifications

Fluorescent Agent Type Labeling
Optical Imaging Classification Fluorescence Imaging
Product Brand Name VivoTag
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Unit Size 5 mg
Wave Length 800 nm
Resources, Events & More
  • All

Application Note

VivoTag 800 (Protocol)

VivoTag® 800 is a red fluorescent labeling agent containing an N-hydroxysuccinimide (NHS)-ester. Labeling reagents, such as VivoTag 800 reagent, are commonly used for labeling proteins. The NHS ester moiety reacts with amino groups at pH 7-9 to form stable amide bonds. Lysines within proteins, including antibodies, are available as targets for this chemical conjugation.,Protein labeling efficiency may vary depending upon the type of protein labeled, so different conjugation ratios may need to be attempted to attain success. For Near Infrared fluorophore conjugation, ratios of fluorophore to protein of 4:1 have been seen to generate effective imaging agents. Not all antibodies or proteins (independent of target specificity) make good imaging agents, due to long half-lives and/or excessive accumulation in non-target sites.

PDF 393 KB

Flyer

Technical Note

VivoTag® 800 (5 mg) (Data Sheet)

VivoTag® 800 is an amine reactive (NHS Ester) near-infrared (NIR) fluorochrome for labeling biomolecules for in vivo imaging applications.

PDF 58 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB